Immuneering to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences:
Cantor Global Healthcare Conference (September 9-11 in New York City)
- Format: Fireside Chat and 1×1 Investor Meetings
- Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET
H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)
- Format: Fireside Chat and 1×1 Investor Meetings
- Date/Time: Monday, September 14, 2026, from 5:00-5:30 pm ET
The fireside chats will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
